BlackRock, Inc. 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS | BlackRock Inc. BLK | 3,755,504 9.900% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS | BlackRock Inc. BLK | 3,755,504 9.900% | 1,240,380 (+49.32%) | Filing |
| 2024-01-26 11:49 am Purchase | 2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | BlackRock Inc. BLK | 2,515,124 7.600% | 1,188,593 (+89.60%) | Filing |
| 2023-02-09 11:01 am Sale | 2023-01-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | BlackRock Inc. BLK | 1,326,531 4.900% | -14,728 (-1.10%) | Filing |
| 2023-02-08 1:16 pm Purchase | 2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | BlackRock Inc. BLK | 1,341,259 5.000% | 1,341,259 (New Position) | Filing |